Open AccessUse of Uric Acid-Lowering Agents Limits Experimental Cyclosporine Nephropathy
Author(s) -
Fernanda Cristina Mazali,
Richard J. Johnson,
Marilda Mazzali
Publication year - 2011
Publication title -
nephron experimental nephrology
Language(s) - English
Resource type - Journals
ISSN - 1660-2129
DOI - 10.1159/000330274
Subject(s) - benzbromarone , hyperuricemia , allopurinol , uricosuric , medicine , uric acid , nephropathy , xanthine oxidase , endocrinology , glomerulosclerosis , febuxostat , fibrosis , pharmacology , kidney , chemistry , proteinuria , biochemistry , diabetes mellitus , enzyme
Hyperuricemia frequently complicates cyclosporine (CsA) therapy. Previous studies have shown that hyperuricemia exacerbates interstitial and vascular lesions in the cyclosporine model. We tested the hypothesis that normalization of uric acid could prevent the development of cyclosporine toxicity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom